TITLE

Agreements/contracts

PUB. DATE
April 2012
SOURCE
Medical Device Daily;4/18/2012, Vol. 16 Issue 75, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive worldwide license granted by Dyax to Eclipse Therapeutics for the development and commercialization of preclinical fully-human antibodies discovered through the phage display technology of Dyax for use in oncology indications.
ACCESSION #
74538261

 

Related Articles

  • Eclipse Breathes New Life Into Biogen Idec Cancer Platform.  // BioWorld Today;4/18/2012, Vol. 23 Issue 75, p1 

    The article reports on the exclusive worldwide license agreement of Eclipse Therapeutics Inc. with Dyax Corp. which will provide Eclipse with multiple antibody candidates targeting cancer stem cells (CSCs) developed using its CSC Rx Discovery platform. The agreement will give Eclipse the license...

  • Dyax and Eclipse Therapeutics Announce Oncology Antibody License Agreement.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article informs that Dyax Corp. has granted Eclipse Therapeutics Inc. the license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax's gold-standard phage display technology for use in oncology indications. In return, Dyax will receive an...

  • Agreements/contracts.  // Medical Device Daily;4/3/2012, Vol. 16 Issue 64, p4 

    The article reports on the licensing agreement signed by GE Healthcare for the development and commercialization of peptides binding to c-Met, under which upfront, milestone and royalty payments will be made to Dyax.

  • Dyax grants use of its antibody phage display libraries to Tanox.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p16 

    Reports that Dyax Corp. has granted a non-exclusive license to its proprietary antibody phage display libraries to Tanox Inc. for the identification and development of antibodies for use in a variety of therapeutic applications. Specialization of Tanox; Terms of the agreement; Statement of...

  • Dyax Partners DX-88 with Cubist in Surgery; Awaits Data in HAE. Boggs, Jennifer // BioWorld Today;4/25/2008, Vol. 19 Issue 81, p1 

    The article reports on the decision of Dyax Corp. to license the North American and European rights for its DX-88 compound for use in preventing blood loss during surgery to Cubis Pharmaceuticals Inc. The potential deal is valued at$231.5 million. Dyax is still awaiting results of its second...

  • Dyax inks partnership for multi-potential DX-88.  // Cardiovascular Devices & Drugs;May2008, Vol. 14 Issue 5, p21 

    The article reports that Dyax has licensed North American and European rights to an intravenous formulation of a compound for use in preventing blood loss during surgery to Cubist Pharmaceuticals in a potential $231.5 deal. The move is part of the multi-step commercialization strategy of Dyax....

  • Fovea, Dyax Sign Agreement for Ophthalmic Indications. Etheridge, James // BioWorld International;2/18/2009, Vol. 14 Issue 7, p5 

    The article reports on an exclusive license agreement entered by Fovea Pharmaceuticals SA and Dyax Corp. for the development and commercialization of an ocular formulation of DX-88 for the treatment of retinal diseases. Under the agreement, Fovea will be granted exclusive marketing rights for...

  • Financings Roundup.  // BioWorld Today;8/7/2008, Vol. 19 Issue 153, p3 

    The article reports that Massachusetts-based Dyax Corp. has agreed to a $50 million loan with Cowen Healthcare Royalty Partners LP. The entry notes that the firm used part of the funds to re-acquire licensing and funded research program revenue interest given to Paul Capital partners' Paul...

  • Dyax Inks Potential $855M Discovery Deal with Biogen Idec. Morrison, Trista // BioWorld Today;2/6/2009, Vol. 20 Issue 24, p1 

    The article reports on the expansion of Dyax Corporation's phage display drug discovery deal with Biogen Idec Inc. a day after an advisory panel of the U.S. Food and Drug Administration (FDA) narrowly backed the approval of Dyax's Kalbitor for acute attacks of hereditary angioedema. Dyax will...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics